Quark Pharmaceuticals to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

FREMONT, Calif., Oct. 22 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that it is scheduled to present on Tuesday, November 6, 2007 at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference and the CIBC World Markets 18th Annual Healthcare Conference. Gavin Samuels, M.D., Senior Vice President of Business Development will be presenting.

Event: CIBC World Markets 18th Annual Healthcare Conference Date: Tuesday, November 6, 2007 Time: 8:30 a.m. ET Place: The Waldorf-Astoria Hotel, New York Event: Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference Date: Tuesday, November 6, 2007 Time: 11:40 a.m. ET Place: New York Palace Hotel, New York About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development and includes:

* A proprietary gene discovery platform (BiFAR(TM)) and algorithm for optimizing siRNA sequencing * Novel siRNA structures that the Company believes provide Quark with freedom to operate in the crowded siRNA intellectual property arena for its future product pipeline * The ability to deliver siRNA locally and systemically to organs including eye, ear, kidney, lung, spinal cord and bone marrow

Quark has a robust product portfolio including two clinical, one pre-IND and six preclinical candidates in development. Its lead product candidates are RTP801i-14, an siRNA molecule in phase I/IIa clinical trial for the treatment of wet age-related macular degeneration that is licensed to Pfizer on an exclusive worldwide basis, AKIi-5, an siRNA molecule for the prevention of acute kidney injury / acute renal failure, and AHLi-11, an siRNA molecule for the prevention of chemotherapy and noise-induced hearing loss.

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at http://www.quarkpharma.com/

Quark Pharmaceuticals, Inc. The Ruth Group Gavin Samuels Stephanie Carrington / Elizabeth Scott (510) 449 6737 (investors) GSamuels@quarkpharma.com (646) 536-7017 / 7014 scarrington@theruthgroup.com escott@theruthgroup.com Janine McCargo (media) (646) 536-7033 jmccargo@theruthgroup.com

Quark Pharmaceuticals, Inc.

CONTACT: Gavin Samuels of Quark Pharmaceuticals, Inc., 1-510-449-6737,
GSamuels@quarkpharma.com; or Investors: Stephanie Carrington, 1-646-536-7017,
scarrington@theruthgroup.com, or Elizabeth Scott, 1-646-536-7014,
escott@theruthgroup.com; or Media: Janine McCargo, 1-646-536-7033,
jmccargo@theruthgroup.com, all of The Ruth Group

Web site: http://www.quarkpharma.com/